ريزدرونات تيڤع ٣٥ ملغ

main_info

  • trade_name:
  • ريزدرونات تيڤع ٣٥ ملغ
  • pharmaceutical_form:
  • TABLETS
  • administration_route:
  • PER OS
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic
  • manufactured_by:
  • TEVA PHARMACEUTICAL WORKS PRIVATE LIMITED COMPANY, HUNGARY

documents

localization

  • country:
  • ريزدرونات تيڤع ٣٥ ملغ
    إسرائيل
  • language:
  • العربية

therapeutic_information

  • therapeutic_group:
  • RISEDRONIC ACID
  • therapeutic_indication:
  • Treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.

status

  • source:
  • Ministry of Health - State of Israel
  • authorization_number:
  • 96633117300
  • authorization_date:
  • 01-10-2011
  • last_update:
  • 09-08-2016

doc_PIL: head_title_medicine_info

Risedronatetevamoh,26/12/10,SZ

®

"# $

RisedronateSodium35mg

Lactosemonohydrate,pregelatinizedstarch,starch,colloidalsilicondioxide,sodiumstearyl

fumarate,magnesiumstearate,hypromellose,titaniumdioxide,macrogol/PEG400,ironoxide

yellow,polysorbate80,FD&Cyellow#6/sunsetyellowFCFaluminumlake,ironoxidered.

" # $ % &

& %

" !

& "

"

" "

" $ D

" !

" ! ! !

& ®

"

" )

"

"

" "

2

Risedronatetevamoh,26/12/10,SZ

osteonecrosis

& '

" ( %

& $ %

& ! $

+++++++++++++++++++++++++++++++++++++++++++

+++++++++++++++++++++++++++++++++++++++++++

"

" ! "

" )

" " " "

" !

-*. /&

0&// !